These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 23063647)

  • 1. Prazosin, an α(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease.
    Katsouri L; Vizcaychipi MP; McArthur S; Harrison I; Suárez-Calvet M; Lleo A; Lloyd DG; Ma D; Sastre M
    Neurobiol Aging; 2013 Apr; 34(4):1105-15. PubMed ID: 23063647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis.
    Scullion GA; Kendall DA; Marsden CA; Sunter D; Pardon MC
    Neuropharmacology; 2011; 60(2-3):223-34. PubMed ID: 20850464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-O-methylhonokiol prevents memory impairment in the Tg2576 transgenic mice model of Alzheimer's disease via regulation of β-secretase activity.
    Lee YJ; Choi DY; Lee YK; Lee YM; Han SB; Kim YH; Kim KH; Nam SY; Lee BJ; Kang JK; Yun YW; Oh KW; Hong JT
    J Alzheimers Dis; 2012; 29(3):677-90. PubMed ID: 22330831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
    Fabbro S; Schaller K; Seeds NW
    J Neurochem; 2011 Sep; 118(5):928-38. PubMed ID: 21689108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's disease transgenic mouse model.
    Zhang X; Heng X; Li T; Li L; Yang D; Zhang X; Du Y; Doody RS; Le W
    J Alzheimers Dis; 2011; 24(4):739-49. PubMed ID: 21321394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
    J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebral microinjection of interleukin-4/interleukin-13 reduces β-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice.
    Kawahara K; Suenobu M; Yoshida A; Koga K; Hyodo A; Ohtsuka H; Kuniyasu A; Tamamaki N; Sugimoto Y; Nakayama H
    Neuroscience; 2012 Apr; 207():243-60. PubMed ID: 22342341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease.
    Guzmán-Ramos K; Moreno-Castilla P; Castro-Cruz M; McGaugh JL; Martínez-Coria H; LaFerla FM; Bermúdez-Rattoni F
    Learn Mem; 2012 Sep; 19(10):453-60. PubMed ID: 22984283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
    Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.
    Morgan D; Diamond DM; Gottschall PE; Ugen KE; Dickey C; Hardy J; Duff K; Jantzen P; DiCarlo G; Wilcock D; Connor K; Hatcher J; Hope C; Gordon M; Arendash GW
    Nature; 2000 Dec 21-28; 408(6815):982-5. PubMed ID: 11140686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
    Chavant F; Deguil J; Pain S; Ingrand I; Milin S; Fauconneau B; Pérault-Pochat MC; Lafay-Chebassier C
    J Pharmacol Exp Ther; 2010 Feb; 332(2):505-14. PubMed ID: 19889791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yokukansan, a traditional Japanese medicine, ameliorates memory disturbance and abnormal social interaction with anti-aggregation effect of cerebral amyloid β proteins in amyloid precursor protein transgenic mice.
    Fujiwara H; Takayama S; Iwasaki K; Tabuchi M; Yamaguchi T; Sekiguchi K; Ikarashi Y; Kudo Y; Kase Y; Arai H; Yaegashi N
    Neuroscience; 2011 Apr; 180():305-13. PubMed ID: 21303686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
    He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
    Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of Alzheimer's disease.
    Choi IS; Lee YJ; Choi DY; Lee YK; Lee YH; Kim KH; Kim YH; Jeon YH; Kim EH; Han SB; Jung JK; Yun YP; Oh KW; Hwang DY; Hong JT
    J Alzheimers Dis; 2011; 27(1):127-41. PubMed ID: 21799245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease.
    Hashimoto T; Ogino K; Shin RW; Kitamoto T; Kikuchi T; Shimizu N
    Neurosci Lett; 2010 Jan; 469(2):273-7. PubMed ID: 20025930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.
    Grossi C; Francese S; Casini A; Rosi MC; Luccarini I; Fiorentini A; Gabbiani C; Messori L; Moneti G; Casamenti F
    J Alzheimers Dis; 2009; 17(2):423-40. PubMed ID: 19363260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease.
    Onozuka H; Nakajima A; Matsuzaki K; Shin RW; Ogino K; Saigusa D; Tetsu N; Yokosuka A; Sashida Y; Mimaki Y; Yamakuni T; Ohizumi Y
    J Pharmacol Exp Ther; 2008 Sep; 326(3):739-44. PubMed ID: 18544674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.